- Email: [email protected]
CME
CME INFORMATION Hyponatremia in Congestive Heart Failure Educational Objectives After reviewing this supplement, participants will be able to ● ● ● ● ●
Discuss the neurohormonal systems that are activated in congestive heart failure (CHF) Describe the pathophysiology of hyponatremia in the patient with CHF Identify patients at highest risk for having or developing hyponatremia Explain the consequences of untreated hyponatremia Discuss available therapies for hyponatremia
Target Audience This program has been developed for cardiologists and other physicians concerned with electrolyte disorders associated with CHF.
Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the (ACCME) by the Elsevier Office of Continuing Medical Education (EOCME). The EOCME is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit The EOCME designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Acknowledgment This program is supported by an educational grant from Astellas Pharma US, Inc.
Disclosure This supplement contains references to off-label/unapproved uses of medication.
Hyponatremia in Congestive Heart Failure Guest Editor Kanu Chatterjee, MB Ernest Gallo Distinguished Professor of Medicine Chatterjee Center for Cardiac Research Division of Cardiology University of California, San Francisco San Francisco, California, USA Faculty Steven R. Goldsmith, MD Associate Director Cardiology Division Hennepin County Medical Center University of Minnesota Minneapolis, Minnesota, USA
Ron M. Oren, MD Professor of Clinical Medicine Department of Internal Medicine Heart Failure Treatment Program University of Iowa College of Medicine Iowa City, Iowa, USA
Faculty Disclosures The Elsevier Office of Continuing Medical Education (EOCME) adheres to ACCME Standards regarding industry support of continuing medical education. As a sponsor accredited by the ACCME, the EOCME requires the disclosure of any significant financial interest or other relationship a faculty member has with the manufacturer of any commercial drug or product as well as disclosure of discussion of any unapproved uses of drugs or products. The faculty of this CME activity have disclosed the following: Kanu Chatterjee, MB, has received grant/research support from CV Therapeutics, Scios Inc., and Astellas Pharma US, Inc.; and is a member of the Speakers’ Bureau for Bristol-Myers Squibb Company, Scios Inc., and Merck & Co. Steven R. Goldsmith, MD, serves as a consultant to Astellas Pharma US, Inc. Ron M. Oren, MD, has no financial arrangement or affiliation with any corporate organization or manufacturer of a product discussed in this activity.
Discuss the neurohormonal systems that are activated in congestive heart failure (CHF) Describe the pathophysiology of hyponatremia in the patient with CHF Identify patients at highest risk for having or developing hyponatremia Explain the consequences of untreated hyponatremia Discuss available therapies for hyponatremia
Target Audience This program has been developed for cardiologists and other physicians concerned with electrolyte disorders associated with CHF.
Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the (ACCME) by the Elsevier Office of Continuing Medical Education (EOCME). The EOCME is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit The EOCME designates this educational activity for a maximum of 3 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Acknowledgment This program is supported by an educational grant from Astellas Pharma US, Inc.
Disclosure This supplement contains references to off-label/unapproved uses of medication.
Hyponatremia in Congestive Heart Failure Guest Editor Kanu Chatterjee, MB Ernest Gallo Distinguished Professor of Medicine Chatterjee Center for Cardiac Research Division of Cardiology University of California, San Francisco San Francisco, California, USA Faculty Steven R. Goldsmith, MD Associate Director Cardiology Division Hennepin County Medical Center University of Minnesota Minneapolis, Minnesota, USA
Ron M. Oren, MD Professor of Clinical Medicine Department of Internal Medicine Heart Failure Treatment Program University of Iowa College of Medicine Iowa City, Iowa, USA
Faculty Disclosures The Elsevier Office of Continuing Medical Education (EOCME) adheres to ACCME Standards regarding industry support of continuing medical education. As a sponsor accredited by the ACCME, the EOCME requires the disclosure of any significant financial interest or other relationship a faculty member has with the manufacturer of any commercial drug or product as well as disclosure of discussion of any unapproved uses of drugs or products. The faculty of this CME activity have disclosed the following: Kanu Chatterjee, MB, has received grant/research support from CV Therapeutics, Scios Inc., and Astellas Pharma US, Inc.; and is a member of the Speakers’ Bureau for Bristol-Myers Squibb Company, Scios Inc., and Merck & Co. Steven R. Goldsmith, MD, serves as a consultant to Astellas Pharma US, Inc. Ron M. Oren, MD, has no financial arrangement or affiliation with any corporate organization or manufacturer of a product discussed in this activity.